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Abstract
The ability to demonstrate tumour foci that are undetected by conventional imaging has resulted in the emergence of
positron emission tomography (PET) as a valuable clinical tool in oncology. This article describes the technique and
indications for fluorine-18 labelled fluorodeoxyglucose (18FDG)-PET in lung cancer, demonstrating the high accuracy
and cost-effectiveness of 18FDG-PET in the characterisation of solitary pulmonary nodules and in the pre-operative
staging of non-small cell lung cancer. Emerging roles in determination of prognosis, radiotherapy planning, therapy
monitoring and diagnosis of recurrence are illustrated.
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Introduction
After many years of application in research, positron
emission tomography (PET) is now emerging as a valu-
able clinical tool, particularly in the field of oncological
imaging. This transition has resulted largely from the
development of one particular PET radiotracer, fluorine-
18 labelled fluorodeoxyglucose (18FDG). The relatively
long half-life of Fluorine-18 (110 min) has meant that
PET units no longer require their own cyclotron for iso-
tope production as Fluorine-18 from one cyclotron can be
transported to several PET scanners at sites remote from
the production facility. Furthermore, Flourine-18 imaging
is not associated with the high count rates obtained with
other shorter-lived isotopes, allowing lower cost sodium
iodide (Nal) detector systems to be used in preference
to Bismuth Germinate (BGO). Nal detector systems also
benefit from greater energy resolution, allowing superior
rejection of scattered photons and thereby enhancing
imaging quality for whole body studies.
18FDG demonstrates high uptake in many cancers,
including lung cancer. Uptake results from increased
expression of hexokinase and of Glut-1 glucose trans-
porters on the cell surface. Both of these metabolic
changes result from oncogene mutations with the tumour
cells, most notably the p53 gene-mutation, which occurs
commonly in lung cancer. It is important to realise
that the detection of a tumour focus on 18FDG-PET is
determined by the degree of metabolic change rather than
the size of the lesion (Fig. 1). The high glucose metabolic
rate of tumours as compared to normal tissues allows
tumour foci as small as 3 mm to be commonly identified
by PET.
Lung cancer is an important indication for PET
imaging [1,2], accounting for approximately one quarter
of the patients examined at the Wesley PET Centre. This
article describes the technique and indications for PET
in lung cancer and reports on its accuracy and cost-
effectiveness.
Technique
After a six-hour fast to ensure low blood glucose levels,
patients are injected with 185–370 MBq 18FDG and
This paper is available online at http://www.cancerimaging.org. In the event of a change in the URL address, please use the DOI
provided to locate the paper.
1470-7330/02/000087 + 03 c© 2002 International Cancer Imaging Society
88 K A Miles
imaging of the chest, abdomen and pelvis is performed
one hour later. The brain is not routinely imaged, as
detection of small cerebral metastases is unreliable, due
to masking by the high uptake seen in normal cerebral
cortices. A dedicated PET system (Nal or BGO) should
be used, because the low sensitivity of coincidence
gamma camera systems results in failure to detect small
nodal metastases [3]. Attenuation correction is essential to
optimise the detection and localisation of deep lesions.
Image reconstruction should employ iterative (OSEM)
techniques to further enhance the quality of final images.
Tumour uptake can be quantified by measurement of the





Figure 1 An illustration of how the detection of
small tumours by PET is not determined by spatial
resolution. The text on the left is displayed with high
spatial resolution but is unable to detect the hidden
message ‘CANCER’. Even though the text on the
right is blurred (low resolution), the hidden message
is revealed by labelling the letters that are functionally
different (i.e. they carry the hidden message).
Applications
Solitary pulmonary nodules
18FDG-PET is highly accurate in the characterisa-
tion of solitary pulmonary nodules (SPN), diagnosing
malignancy with reported sensitivities of 89–100%
and specificities of 58–100% [1]. Thus, 18FDG-PET
is generally more accurate than per-cutaneous biopsy,
which has lower sensitivity due to sampling error. In
up to 50% of positive cases, PET also identifies sites
of metastasis that have not been suspected on the
basis of other imaging. Specificity values for 18FDG-
PET are lower in populations with a high incidence of
granulomatous diseases, such as histoplasmosis, which
may produce false-positive results. Other benign causes
of 18FDG uptake include tuberculosis, aspergillosis and
pulmonary infarction. False-negative studies can occur
with alveolar cell carcinoma and carcinoid tumours, and
therefore follow-up imaging is recommended following
a negative study for SPN. Accuracy can be improved
by reporting the PET data with CT data available for
comparison. Experience with 18FDG-PET, along with
decision tree analysis techniques, have shown that the
high accuracy of PET for SPN translates to reductions
in health care expenditure by avoidance of unnecessary
biopsy procedures and thoracotomies [4,5].
Pre-operative staging of non-small cell lung
cancer
18FDG-PET is more accurate for staging mediastinal
nodes than CT (PET sensitivity 77–82%, specificity
81–98%; CT sensitivity 56–65%, specificity 44–87%).
PET will identify involved nodes that are too small to
be reliably diagnosed by CT, whereas the absence of
18FDG uptake in nodes that are seen to be enlarged
on CT indicates reactive adenopathy. Distant metastases,
especially in bone or adrenal glands, are also accurately
depicted by 18FDG-PET. The high therapeutic impact of
18FDG-PET is shown by the fact that significant changes
in management occur in 32–51% of patients examined.
Patients classified as stage 1 by PET demonstrate
improved survival as compared to those considered to
be Stage 1 on CT [6]. This improvement results from the
ability of PET to identify those patients most likely to
benefit from surgery. Furthermore, the high accuracy of
PET has been shown to lead to savings in health care
expenditure by allowing unnecessary thoracotomy to be
avoided in those patients unlikely to benefit [5,7,8].
Other applications in lung cancer
Emerging roles for 18FDG-PET in lung cancer include
determination of prognosis, radiotherapy planning, ther-
apy monitoring and diagnosis of recurrence. Prognostic
information can be obtained from measurements of
uptake with high SUV values implying a poor prognosis
and a poorer response to radiotherapy [9]. The use
of PET for radiotherapy planning may improve the
efficacy of treatment by ensuring that tumour revealed
by PET, but undetected by CT, is not excluded from the
treatment volume [10]. The reduction in 18FDG uptake
following radiotherapy correlates with the long-term
therapeutic response, and PET is more accurate than CT
in predicting the down-staging that has occurred with
induction chemotherapy. 18FDG-PET is also useful in
diagnosing recurrent tumour, particularly when CT is
unable to distinguish between recurrent tumour and post-
therapy fibrosis in the presence of a residual structural
abnormality.
Conclusion
There is now a substantial body of evidence supporting
the use of 18FDG-PET in lung cancer. The value
of the technique is increasingly recognised by health
purchasers. The high accuracy of 18FDG-PET allows
selection of the most appropriate and effective therapy for
patients with lung cancer.
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Key points
(1) 18FDG-PET is accurate and cost-effective in the
characterisation of SPN and in the pre-operative
staging of non-small cell lung cancer.
(2) 18FDG-PET has emerging roles in determination of
prognosis, radiotherapy planning, therapy monitor-
ing and diagnosis of recurrence.
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